Topline data readout from Phase 3 LUCIDITY clinical trial of avexitide in post-bariatric hypoglycemia on track; anticipated in Q3 2026 ...
Barchart Research What to Expect from AMLX Earnings AMLX Generated May 6, 2026 Current Price $16.06 EPS Estimate $$-0.34 Consensus Rating Strong Buy Average Move 4.73% Amylyx's Pivot From Neurodegenerative...
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that management will participate in the following upcoming investor conferences, which are being...
The Expanded Access Program allows eligible adults with post-bariatric hypoglycemia following Roux-en-Y gastric bypass surgery access to avexitide, an investigational, first-in-class glucagon-like peptide-1...
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) will report its first quarter 2026 financial results on Thursday, May 7, 2026. Amylyx’s senior management team...
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that management will present at the 25th Annual Needham Virtual Healthcare Conference. The corporate...
Last participant has been randomized and dosed in the LUCIDITY trial of avexitide; LUCIDITY enrolled a total of 78 participants Topline data readout on...
Recruitment of the pivotal Phase 3 LUCIDITY trial of avexitide in PBH is complete; continue to expect to randomize and dose last eligible participants in Q1 2026, with topline data anticipated in Q3 2026...
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that management will participate in the following upcoming investor conferences, which are being...